Compare
Champions Oncology, Inc. vs Protalix BioTherapeutics, Inc. vs Vir Biotechnology, Inc. vs Compugen Ltd
| Latest fiscal year | Champions Oncology, Inc. CSBR | Protalix BioTherapeutics, Inc. PLX | Vir Biotechnology, Inc. VIR | Compugen Ltd CGEN |
|---|---|---|---|---|
| Year ended | 2026-04-30 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $59.42M | $52.74M | $68.56M | $72.76M |
| Revenue growth (YoY) | +4.4% | -1.2% | -7.6% | +161.1% |
| Gross margin | 48.0% (computed) | 48.8% (computed) | n/a | 87.3% |
| Operating margin | -1.9% | -10.4% | -699.2% | 43.1% |
| Net margin | -2.0% | -12.5% | -638.9% | 48.6% |
| Net income | -$1.18M | -$6.60M | -$437.99M | $35.34M |
| EPS (Diluted) | -$0.08 | -$0.08 | -$3.16 | $0.38 |
| Operating cash flow | -$4.47M | -$11.99M | -$391.78M | $31.63M |
| Free cash flow | -$5.04M | -$13.63M | -$396.61M | $31.33M |
| Cash & equivalents | n/a | $14.68M | $232.19M | $90.60M |
| Total assets | $26.99M | $82.35M | $1.00B | $156.57M |
| Total liabilities | $22.92M | $34.12M | $237.55M | n/a |
| Shareholders' equity | $3.94M | $48.23M | $765.28M | $102.73M |
| Return on year-end equity | -29.8% | -13.7% | -57.2% | 34.4% |
| Shares outstanding | 13.89M | 80.43M | 139.47M | 94.55M |
Revenue, most recent five fiscal years
| Fiscal year | Champions Oncology, Inc. | Protalix BioTherapeutics, Inc. | Vir Biotechnology, Inc. | Compugen Ltd |
|---|---|---|---|---|
| Latest | $59.42M Ended 2026-04-30 | $52.74M Ended 2025-12-31 | $68.56M Ended 2025-12-31 | $72.76M Ended 2025-12-31 |
| 1 year earlier | $56.94M Ended 2025-04-30 | $53.40M Ended 2024-12-31 | $74.20M Ended 2024-12-31 | $27.86M Ended 2024-12-31 |
| 2 years earlier | $50.16M Ended 2024-04-30 | $65.49M Ended 2023-12-31 | $86.18M Ended 2023-12-31 | $33.46M Ended 2023-12-31 |
| 3 years earlier | $53.87M Ended 2023-04-30 | $47.64M Ended 2022-12-31 | $1.62B Ended 2022-12-31 | $7.50M Ended 2022-12-31 |
| 4 years earlier | $49.11M Ended 2022-04-30 | $38.35M Ended 2021-12-31 | $1.10B Ended 2021-12-31 | $6.00M Ended 2021-12-31 |